A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable Primary Non-Small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease

Inclusion Criteria:

- Histologically confirmed non-small cell lung cancer (NSCLC)

- Patients with resectable primary NSCLC who are undergoing surgery to resect T3 to T4
lesions OR any patients with clinical NI or N2 disease regardless of T-stage

- Subjects must have an Eastern Cooperative Oncology Group (ECOG) scale of 0-2

- Subjects of child-bearing potential must agree to use adequate contraceptive methods
(e.g., hormonal or barrier method of birth control; abstinence) prior to study entry
and for the duration of study participation; should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study, she
should inform her treating physician immediately

- The subject or legal representative must understand the investigational nature of
this study and sign an Independent Ethics Committee/Institutional Review Board
approved written informed consent prior to receiving any study related procedure

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients with known brain metastases should be excluded from this clinical trial

- Patients with porphyria, or with known hypersensitivity to porphyrins or
porphyrin-like compounds

- White blood cell (WBC) < 4,000

- Platelet count < 100,000

- Prothrombin time 1.5 times above the upper normal limit

- Total serum bilirubin > 2 mg/dL

- Serum creatinine > 2 mg/dL

- Alkaline phosphatase (hepatic) or serum glutamic oxaloacetic transaminase (SGOT) > 3
times the upper normal limit

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant or nursing female subjects

- Unwilling or unable to follow protocol requirements

- Any condition which in the Investigator's opinion deems the subject an unsuitable
candidate to receive study drug

- Received an investigational agent within 30 days prior to enrollment